Loading...

Profound Medical

TSX:PRN
Snowflake Description

Excellent balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
PRN
TSX
CA$78M
Market Cap
  1. Home
  2. CA
  3. Healthcare
Company description

Profound Medical Corp. operates as a medical technology company focuses on magnetic resonance guided ablation procedures in Canada, Germany, and Finland. The last earnings update was 73 days ago. More info.


Add to Portfolio Compare Print
  • Profound Medical has significant price volatility in the past 3 months.
PRN Share Price and Events
7 Day Returns
10.8%
TSX:PRN
-1.4%
CA Medical Equipment
-0.5%
CA Market
1 Year Returns
-20.9%
TSX:PRN
-12.9%
CA Medical Equipment
-2.9%
CA Market
PRN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Profound Medical (PRN) 10.8% -11.1% -17.2% -20.9% -44.6% -
CA Medical Equipment -1.4% -3.7% -9.3% -12.9% -58.1% -83.5%
CA Market -0.5% 0.8% -2.1% -2.9% 8% 0.6%
1 Year Return vs Industry and Market
  • PRN underperformed the Medical Equipment industry which returned -12.9% over the past year.
  • PRN underperformed the Market in Canada which returned -2.9% over the past year.
Price Volatility
PRN
Industry
5yr Volatility vs Market

Value

 Is Profound Medical undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Profound Medical. This is due to cash flow or dividend data being unavailable. The share price is CA$0.72.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Profound Medical's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Profound Medical's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
TSX:PRN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in CAD CA$-0.17
TSX:PRN Share Price ** TSX (2019-07-17) in CAD CA$0.72
North America Medical Equipment Industry PE Ratio Median Figure of 66 Publicly-Listed Medical Equipment Companies 41.39x
Canada Market PE Ratio Median Figure of 538 Publicly-Listed Companies 15.05x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Profound Medical.

TSX:PRN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSX:PRN Share Price ÷ EPS (both in CAD)

= 0.72 ÷ -0.17

-4.15x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Profound Medical is loss making, we can't compare its value to the North America Medical Equipment industry average.
  • Profound Medical is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does Profound Medical's expected growth come at a high price?
Raw Data
TSX:PRN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.15x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
14.6%per year
North America Medical Equipment Industry PEG Ratio Median Figure of 56 Publicly-Listed Medical Equipment Companies 2.26x
Canada Market PEG Ratio Median Figure of 248 Publicly-Listed Companies 1.16x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Profound Medical, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Profound Medical's assets?
Raw Data
TSX:PRN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in CAD CA$0.22
TSX:PRN Share Price * TSX (2019-07-17) in CAD CA$0.72
Canada Medical Equipment Industry PB Ratio Median Figure of 16 Publicly-Listed Medical Equipment Companies 5.35x
Canada Market PB Ratio Median Figure of 2,440 Publicly-Listed Companies 1.42x
TSX:PRN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSX:PRN Share Price ÷ Book Value per Share (both in CAD)

= 0.72 ÷ 0.22

3.26x

* Primary Listing of Profound Medical.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Profound Medical is good value based on assets compared to the CA Medical Equipment industry average.
X
Value checks
We assess Profound Medical's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Profound Medical has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Profound Medical expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
14.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Profound Medical expected to grow at an attractive rate?
  • Unable to compare Profound Medical's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Profound Medical's earnings growth to the Canada market average as it is expected to be loss making during the next 1-3 years.
  • Profound Medical's revenue growth is expected to exceed the Canada market average.
Annual Growth Rates Comparison
Raw Data
TSX:PRN Future Growth Rates Data Sources
Data Point Source Value (per year)
TSX:PRN Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 14.6%
TSX:PRN Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 47.6%
Canada Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 38.4%
Canada Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 33.8%
Canada Market Earnings Growth Rate Market Cap Weighted Average 14%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
TSX:PRN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
TSX:PRN Future Estimates Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 71 -19 1
2022-12-31 66 18 -4 2
2021-12-31 42 7 -10 2
2020-12-31 22 0 -12 3
2019-12-31 7 -17 -18 3
TSX:PRN Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-03-31 4 -18 -19
2018-12-31 3 -18 -21
2018-09-30 3 -19 -20
2018-06-30 4 -16 -21
2018-03-31 5 -15 -20
2017-12-31 5 -15 -19
2017-09-30 3 -15 -19
2017-06-30 2 -15 -18
2017-03-31 1 -15 -17
2016-12-31 -15 -16
2016-09-30 -11 -14
2016-06-30 -11 -13

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Profound Medical is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Profound Medical's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
TSX:PRN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Profound Medical Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

TSX:PRN Future Estimates Data
Date (Data in CAD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -0.16 -0.16 -0.16 1.00
2022-12-31 -0.23 -0.23 -0.23 1.00
2021-12-31 -0.24 -0.24 -0.24 1.00
2020-12-31 -0.15 -0.09 -0.21 2.00
2019-12-31 -0.17 -0.16 -0.18 3.00
TSX:PRN Past Financials Data
Date (Data in CAD Millions) EPS *
2019-03-31 -0.17
2018-12-31 -0.21
2018-09-30 -0.22
2018-06-30 -0.26
2018-03-31 -0.29
2017-12-31 -0.31
2017-09-30 -0.35
2017-06-30 -0.36
2017-03-31 -0.37
2016-12-31 -0.39
2016-09-30 -0.36
2016-06-30 -0.33

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Profound Medical is expected to make outstanding use of shareholders’ funds in the future (Return on Equity greater than 40%).
X
Future performance checks
We assess Profound Medical's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Profound Medical has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Profound Medical performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Profound Medical's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Profound Medical does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Profound Medical's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Profound Medical's 1-year growth to the North America Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
Profound Medical's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Profound Medical Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

TSX:PRN Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 3.70 -18.75 9.48 10.43
2018-12-31 2.60 -20.76 10.75 10.27
2018-09-30 2.78 -20.43 10.51 9.63
2018-06-30 3.95 -20.82 10.19 9.87
2018-03-31 4.69 -19.65 9.10 10.30
2017-12-31 4.90 -18.82 9.14 9.64
2017-09-30 3.01 -19.08 9.38 9.79
2017-06-30 1.55 -17.62 8.40 9.40
2017-03-31 0.59 -16.61 7.14 9.05
2016-12-31 -16.33 5.99 9.65
2016-09-30 -14.31 4.91 8.45
2016-06-30 -13.20 4.69 7.65
2016-03-31 -18.26 6.77 6.63
2015-12-31 -16.38 6.24 4.98
2015-09-30 -16.01 6.22 4.35
2015-06-30 -14.59 5.47 3.15
2015-03-31 -9.82 2.43 2.52
2014-12-31 -8.20 2.16 2.17
2013-12-31 -14.21 1.37 1.93
2012-12-31 -9.01 1.34 1.77

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Profound Medical has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Profound Medical has efficiently used its assets last year compared to the North America Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Profound Medical improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Profound Medical's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Profound Medical has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Profound Medical's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Profound Medical's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Profound Medical is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Profound Medical's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Profound Medical's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Profound Medical Company Filings, last reported 3 months ago.

TSX:PRN Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 23.89 11.93 27.05
2018-12-31 26.63 11.96 30.69
2018-09-30 31.11 11.79 35.21
2018-06-30 36.01 3.72 32.00
2018-03-31 41.62 3.80 38.01
2017-12-31 14.14 5.15 11.10
2017-09-30 18.38 5.37 16.31
2017-06-30 6.62 5.27 10.67
2017-03-31 10.83 6.92 16.89
2016-12-31 14.84 6.64 20.83
2016-09-30 2.92 6.37 9.57
2016-06-30 6.85 6.11 12.97
2016-03-31 10.33 5.89 16.98
2015-12-31 13.96 5.85 20.52
2015-09-30 16.66 5.61 23.28
2015-06-30 19.34 5.38 25.96
2015-03-31 -39.84 15.61 0.49
2014-12-31 -37.94 12.49 0.41
2013-12-31 -27.73 9.15 0.61
2012-12-31 -14.65 5.84 0.57
  • Profound Medical's level of debt (49.9%) compared to net worth is high (greater than 40%).
  • Profound Medical had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Profound Medical has sufficient cash runway for 1.5 years based on current free cash flow.
  • Profound Medical has sufficient cash runway for 1.5 years if free cash flow continues to grow at historical rates of 15.4% each year.
X
Financial health checks
We assess Profound Medical's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Profound Medical has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Profound Medical's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Profound Medical dividends.
If you bought CA$2,000 of Profound Medical shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Profound Medical's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Profound Medical's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
TSX:PRN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
North America Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 24 Stocks 1.2%
Canada Market Average Dividend Yield Market Cap Weighted Average of 336 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.1%
Canada Bottom 25% Dividend Yield 25th Percentile 2.1%
Canada Top 25% Dividend Yield 75th Percentile 5.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

TSX:PRN Future Dividends Estimate Data
Date (Data in CA$) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Profound Medical has not reported any payouts.
  • Unable to verify if Profound Medical's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Profound Medical's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Profound Medical has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Profound Medical's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Profound Medical afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Profound Medical has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Profound Medical's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Arun Menawat
COMPENSATION CA$855,665
AGE 64
TENURE AS CEO 2.9 years
CEO Bio

Dr. Arun Swarup Menawat, Ph.D., MBA, has been the Chief Executive Officer of Profound Medical Corp. since August 15, 2016. Dr. Menawat served as the Chief Executive Officer and President of Novadaq Technologies Inc. since April 2003 until July 6, 2016. Dr. Menawat served as President and Chief Operating Officer of Merge Healthcare Canada Corp., (also known as Cedara Software Corp.) until November 25, 2002. He served as Vice President of Operations at Tenneco Inc., where he introduced 84 new products in a single year. He served as Business Manager and Research & Development Manager at Hercules, Inc. He served as President of Coils. He has spent many years developing a solid understanding of the medical imaging based diagnostic and therapeutic procedures. He serves as the Chairman of the Board at ElMindA Ltd. Dr. Menawat led Stereotaxis, Inc to an IPO in the Canadian TSX and US NASDAQ listing. Dr. Menawat has an accomplished history of executive leadership success in the healthcare industry. He served as the Chairman of Novadaq Technologies Inc. since 2015 until July 6, 2016. He has been a Director of MedCurrent Corporation since March 2014 and Profound Medical Corp. since June 04, 2015. He has been an Independent Director of Stereotaxis, Inc. since September 29, 2016. He served as a Director of Novadaq Technologies Inc., since July 2003 until July 6, 2016. He served as a Director of Mira IV Acquisition Corp. He served as a Director of Cedara Software Corp. Dr. Menawat holds a B.S. in Biology from University of District of Columbia, an M.S. and Ph.D., in Chemical (Bio) Engineering, from the University of Maryland and a fellowship in biomedical engineering from the National Institutes of Health. He also earned an Executive MBA from the J.L. Kellogg School of Management, Northwestern University. In 2014, Dr. Menawat was named the EY Ontario Entrepreneur of the Year in the health sciences category. He also earned an Executive MBA from the J.L. Kellogg School of Management, Northwestern University, Evanston, Illinois.

CEO Compensation
  • Arun's compensation has increased whilst company is loss making.
  • Arun's remuneration is higher than average for companies of similar size in Canada.
Management Team

Arun Menawat

TITLE
CEO & Director
COMPENSATION
CA$856K
AGE
64
TENURE
2.9 yrs

Aaron Davidson

TITLE
CFO & Senior VP of Corporate Development
COMPENSATION
CA$1M
AGE
51
TENURE
1.2 yrs

Stephen Kilmer

TITLE
Investor Relations
Board of Directors Tenure

Average tenure and age of the Profound Medical board of directors in years:

4.1
Average Tenure
56
Average Age
  • The tenure for the Profound Medical board of directors is about average.
Board of Directors

Arun Menawat

TITLE
CEO & Director
COMPENSATION
CA$856K
AGE
64
TENURE
4.1 yrs

Ken Galbraith

TITLE
Director
COMPENSATION
CA$48K
AGE
56
TENURE
2.5 yrs

Eric Klein

TITLE
Member of Clinical Advisory Board

Jean-François Pariseau

TITLE
Independent Director
AGE
49
TENURE
4.1 yrs

Peter Albertsen

TITLE
Member of Clinical Advisory Board

Scott Eggener

TITLE
Member of Clinical Advisory Board

Adam Kibel

TITLE
Member of Clinical Advisory Board

Aytekin Oto

TITLE
Member of Clinical Advisory Board

Ian Thompson

TITLE
Member of Clinical Advisory Board

Clare Tempany-Afdhal

TITLE
Member of Clinical Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
04. Dec 18 Buy Arun Menawat Individual 03. Dec 18 04. Dec 18 153,700 CA$0.69 CA$102,874
02. Oct 18 Buy Ian Heynen Individual 28. Sep 18 28. Sep 18 15,000 CA$0.72 CA$10,800
02. Oct 18 Buy Aaron Davidson Individual 28. Sep 18 28. Sep 18 29,000 CA$0.72 CA$20,880
01. Oct 18 Buy Aaron Davidson Individual 28. Sep 18 28. Sep 18 6,000 CA$0.73 CA$4,380
28. Sep 18 Buy Rashed Dewan Individual 28. Sep 18 28. Sep 18 15,000 CA$0.72 CA$10,800
28. Sep 18 Buy Guruprit Singh Individual 28. Sep 18 28. Sep 18 25,000 CA$0.72 CA$18,000
28. Sep 18 Buy Arun Menawat Individual 28. Sep 18 28. Sep 18 137,000 CA$0.72 CA$99,010
X
Management checks
We assess Profound Medical's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Profound Medical has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Who Has Been Buying Profound Medical Corp. (TSE:PRN) Shares?

So we'll take a look at whether insiders have been buying or selling shares in Profound Medical Corp. … For example, a Harvard University study found that 'insider purchases earn abnormal returns of more than 6% per year.' View our latest analysis for Profound Medical The Last 12 Months Of Insider Transactions At Profound Medical In the last twelve months, the biggest single purchase by an insider was when CEO & Director Arun Menawat bought CA$103k worth of shares at a price of CA$0.69 per share. … Happily, the Profound Medical insiders decided to buy shares at close to current prices.

Simply Wall St -

Those Who Purchased Profound Medical (TSE:PRN) Shares Three Years Ago Have A 37% Loss To Show For It

But its virtually certain that sometimes you will buy stocks that fall short of the market average returns. … See our latest analysis for Profound Medical Because Profound Medical is loss-making, we think the market is probably more focussed on revenue and revenue growth, at least for now. … So it makes a lot of sense to check out what analysts think Profound Medical will earn in the future (free profit forecasts).

Simply Wall St -

Is Profound Medical Corp. (TSE:PRN) Excessively Paying Its CEO?

First, this article will compare CEO compensation with compensation at similar sized companies. … How Does Arun Menawat's Compensation Compare With Similar Sized Companies. … is worth CA$95m, and total annual CEO compensation is CA$344k.

Simply Wall St -

Are Profound Medical Corp.'s (TSE:PRN) Interest Costs Too High?

(TSE:PRN) with its market cap of CA$92m, are popular for their explosive growth, investors should also be aware of their balance sheet to judge whether the company can survive a downturn.

Simply Wall St -

Did Profound Medical Corp. (TSE:PRN) Insiders Buy Up More Shares?

So shareholders might well want to know whether insiders have been buying or selling shares in Profound Medical Corp. … But logic dictates you should pay some attention to whether insiders are buying or selling shares. … The Last 12 Months Of Insider Transactions At Profound Medical.

Simply Wall St -

Some Profound Medical Shareholders Are Down 38%

Given that Profound Medical didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. … Shareholders of unprofitable companies usually expect strong revenue growth. … That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.

Simply Wall St -

Does The Profound Medical Corp. (TSE:PRN) Share Price Fall With The Market?

Modern finance theory considers volatility to be a measure of risk, and there are two main types of price volatility. … Some stocks mimic the volatility of the market quite closely, while others demonstrate muted, exagerrated or uncorrelated price movements. … Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility).

Simply Wall St -

What Kind Of Investor Owns Most Of Profound Medical Corp. (TSE:PRN)?

Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies. … Profound Medical is a smaller company with a market capitalization of CA$72m, so it may still be flying under the radar of many institutional investors. … institutional investors have bought into the company.

Simply Wall St -

Is Profound Medical Corp.'s (TSE:PRN) Balance Sheet Strong Enough To Weather A Storm?

While small-cap stocks, such as Profound Medical Corp. … (TSE:PRN) with its market cap of CA$64m, are popular for their explosive growth, investors should also be aware of their balance sheet to judge whether the company can survive a downturn. … Companies operating in the Medical Equipment industry,.

Simply Wall St -

Profound Medical Corp (TSE:PRN): Exploring Free Cash Flows

I will take you through Profound Medical’s cash flow health and the risk-return concept based on the stock’s cash flow yield, using the most recent financial data. … Profound Medical generates cash through its day-to-day business, which needs to be reinvested into the company in order for it to continue operating. … I will be analysing Profound Medical’s FCF by looking at its FCF yield and its operating cash flow growth.

Simply Wall St -

Company Info

Description

Profound Medical Corp. operates as a medical technology company focuses on magnetic resonance guided ablation procedures in Canada, Germany, and Finland. It is developing a treatment to ablate the prostate gland in prostate cancer patients, treatment of uterine fibroids and nerves, and palliative pain treatment for patients with metastatic bone disease. The company is headquartered in Mississauga, Canada.

Details
Name: Profound Medical Corp.
PRN
Exchange: TSX
Founded:
CA$77,812,516
108,072,939
Website: http://www.profoundmedical.com
Address: Profound Medical Corp.
2400 Skymark Avenue,
Unit 6,
Mississauga,
Ontario, L4W 5K5,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSX PRN Common Shares The Toronto Stock Exchange CA CAD 05. Jun 2015
OTCPK PRFM.F Common Shares Pink Sheets LLC US USD 05. Jun 2015
Number of employees
Current staff
Staff numbers
64
Profound Medical employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/18 01:03
End of day share price update: 2019/07/17 00:00
Last estimates confirmation: 2019/07/15
Last earnings filing: 2019/05/06
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.